T. Haws

Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease

W. Hiatt, J. Lepore, E. Hu, 2014, Vascular medicine.

Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.

P. Young, Francoise Powell, T. Burn, 2002, Gene.

A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia

F. Gao, D. Sprecher, J. Lepore, 2019, Clinical pharmacology in drug development.

Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types.

T. Burn, J. Mills, P. Collier, 2002, Endocrinology.

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

S. Russell, R. Gropler, Eric Olson, 2016, JACC. Heart failure.

Unexpected ratio of allozyme expression in diploid and triploid individuals of the clonal hybrid fish Phoxinus eos-neogaeus.

D. L. Letting, K. Goddard, T. Haws, 1999, The Journal of experimental zoology.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

A. Martin, T. Gilmer, S. K. Rudolph, 2007, Cell proliferation.